Diffuse Large B-Cell Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 70+ Companies and 75+ Therapies
DelveInsight's, ' Diffuse Large B-Cell Lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report
Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report
In June 2025, Genmab announced a study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
In June 2025, Mitsubishi Tanabe Pharma Corporation conducted a phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL.
DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies
Diffuse Large B-Cell Lymphoma Emerging Drugs Profile
Brentuximab vedotin: Pfizer
Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
THOR-707: Sanofi
THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.
RNK05047: Ranok Therapeutics
RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.
BMF-219: Biomea Fusion
BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
ADI-001: Adicet Bio
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
The Diffuse Large B-Cell Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.
Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs
Diffuse Large B-Cell Lymphoma Companies
Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
Coverage- Global
Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Diffuse Large B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Brentuximab vedotin: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
THOR-707: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADI-001: Adicet Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Large B-Cell Lymphoma Key Companies
Diffuse Large B-Cell Lymphoma Key Products
Diffuse Large B-Cell Lymphoma- Unmet Needs
Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
Diffuse Large B-Cell Lymphoma Analyst Views
Diffuse Large B-Cell Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Is JD Retail Poised to Ride China's Consumer Rebound in 2025?
's JD core commerce engine, JD Retail, is gaining steady traction as China's consumption environment rebounds and consumers increasingly seek value-driven online experiences. JD Retail continues to play a central role in helping shoppers access quality products at competitive prices while offering brands a powerful and supply-chain-backed platform for scale. With rising user activity, enhanced brand partnerships and deeper category penetration, JD Retail remains the backbone of long-term growth strategy. JD Retail is expanding in high-growth areas like supermarkets, fashion, and food delivery, while reinforcing its low-price strategy. With initiatives like the RMB 200 billion 'export to domestic' program and strong momentum in food delivery, JD is confident that these moves will drive deeper engagement and support long-term growth. To support future growth, JD is accelerating AI adoption across its retail and fulfillment layers. From AI-powered shopping guides and personalized recommendations to automated ad targeting and fulfillment optimization, technology is driving efficiency and improving the experience for users and merchants. JD's 2025 618 campaign followed this playbook and broke records, with over 2.2 billion orders and more than double the number of shoppers year over year. The debut of food delivery and aggressive subsidies during 618 highlights JD's growing ecosystem scale. These efforts are translating into financial strength. In the first quarter of 2025, JD Retail generated revenues of RMB 263.8 billion (US$36.4 billion), accounting for approximately 87.7% of total revenues. With strong execution across categories and deep ecosystem integration, JD Retail looks well-positioned to ride China's consumer rebound through 2025 and beyond. JD Retail's Competition in China JD Retail faces growing competition from Alibaba BABA and PDD Holdings Inc. Sponsored ADR PDD. Alibaba's Tmall and Taobao wrapped up 618 with solid brand growth, highlighting improved merchant tools and sustained consumer demand. Alibaba's platforms emphasized quality over quantity, reflecting a shift toward healthier, service-oriented growth. PDD Holdings, meanwhile, eased its 'lowest price' rule, adopting a 'same product, same price' model to attract more brands. PDD Holdings introduced price protection guarantees and extended its 618 campaign to over a month, using subsidies and flexible pricing to deepen engagement. Both platforms are innovating aggressively to challenge JD's dominance. JD's Price Performance, Valuation and Estimates Shares of have lost 8.4% in the year-to-date (YTD) period against the Zacks Internet - Commerce industry's growth of 4.2% and the Zacks Retail-Wholesale sector's return of 2.8%. JD's YTD Price Performance Image Source: Zacks Investment Research From a valuation standpoint, JD currently trades at a forward 12-month P/E ratio of 7.75X, which is well below the industry's 24.39X. JD has a Value Score of B. JD Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for JD's second-quarter 2025 earnings is pegged at 77 cents per share, which has been revised downward by 20.6% over the past 30 days, indicating a 40.31% year-over-year decline. The Zacks Consensus Estimate for 2025 earnings is pegged at $3.81 per share, which has been revised downward by 8.6% over the past 30 days, indicating a 10.56% year-over-year decline. JD stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Inc. (JD): Free Stock Analysis Report Alibaba Group Holding Limited (BABA): Free Stock Analysis Report PDD Holdings Inc. Sponsored ADR (PDD): Free Stock Analysis Report
National Post
4 hours ago
- National Post
TH Global Capital Named 'Boutique Investment Banking Firm of the Year' for the Third Year Running at the 16th Annual International M&A Awards
Article content LONDON — TH Global Capital, a global boutique investment banking firm with operations across 13 countries in the Americas, Europe, and Asia-Pacific, with a track record of closing transactions in 29 countries, has won four prestigious awards at the 16th Annual International M&A Awards, including 'Boutique Investment Banking Firm of the Year' for the third consecutive year. Article content TH Global Capital's awards include: Article content Boutique Investment Banking Firm of the Year 2025 Corporate/Strategic Deal of the Year ($50MM-$100MM): For advising Cloobees, a Global Salesforce Summit Partner in Poland, on its strategic sale to New York headquartered Synechron. Regional Deal of the Year – Asia: For advising Brainvire, a leading global Digital Commerce and Digital Marketing agency in Asia, on its merger with Said Differently, a Falfurrias portfolio company in the US. M&A Deal of the Year ($50MM–$100MM): For advising Chamonix IT and Exposé, leading Australian companies in Digital Engineering and AI & Data Science respectively, on their strategic sale to Synechron. Article content Presented by the M&A Advisor, the world's premier leadership organization for M&A, restructuring, and corporate finance professionals, these awards recognize TH Global Capital's 24-year track record, global reach, and deep cross-cultural expertise in successfully closing transactions across 29 countries. Article content 'True excellence in dealmaking is defined by clarity of vision, bold leadership, and the ability to create lasting impact,' said Roger Aguinaldo, Founder & CEO of The M&A Advisor. 'As the recipient of the Boutique Investment Banking Firm of the Year award, TH Global Capital exemplifies these qualities. We proudly celebrate TH Global Capital for their exceptional results, surpassing peers, and setting a new standard for success in today's dynamic and competitive marketplace. Article content Vivek Subramanyam Article content TH Global Capital Article content , said: 'It's a tremendous honor to win the 'Boutique Investment Banking Firm of the Year' for the third year in a row. This recognition is a testament to our relentless commitment to excellence and client success over the past 24 years. It reflects not only our team's dedication but also our ability to consistently deliver superior results in an increasingly competitive global market.' Article content Article content Article content
Globe and Mail
4 hours ago
- Globe and Mail
Why AI Stock Astera Labs Was Crushing It This Week
According to data compiled by S&P Global Market Intelligence, Astera Labs (NASDAQ: ALAB) stock's price was floating almost 11% higher week to date on early Friday morning. Investors were mainly reacting to news the tech infrastructure company reported about a new business tie-up with an Asian peer. A cross-Pacific Ocean partnership On Monday, Astera and Taiwanese chipmaker AIChip Technologies announced in a joint press release that they have formed a strategic business partnership. Together, the two will aim to exploit opportunities afforded by sky-high demand for artificial intelligence (AI) functionalities. AIChip, which specializes in application-specific integrated circuit (ASIC) chips, and Astera are teaming up to offer "validated, interoperable solutions for hyperscalers building next-generation AI infrastructure," according to the press release. As the name suggests, a hyperscaler is essentially an extremely large data center. These are in vogue now due to the heavy resource requirements of AI. Aiming to reap a bundle from AI Astera and AIChip offered almost no details about their new partnership, including its financial parameters. Given that, it's tough to gauge how this collaboration might affect their fundamentals. Judging by the market's reaction, though, investors don't seem to mind -- teaming up on projects has clear potential to benefit both companies. I think AI companies like Astera are in the midst of a gold rush. I'd absolutely consider buying the stock. Should you invest $1,000 in Astera Labs right now? Before you buy stock in Astera Labs, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Astera Labs wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
